BIOSTAR PHARMACEUTICALS, INC. BSPM Income Statement

Biostar pharmaceuticals, inc. (BSPM)

Income statement / TTM

Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12
Sales, net
317	962	1,582	2,384	3,904	7,466	21,022	27,129	39,677	50,121	55,144	61,416	58,007	58,366	53,818	52,729	57,041	52,001	45,510	49,317	0	0	0
Cost of sales
354	691	1,012	1,469	2,184	5,238	13,154	16,025	22,562	26,845	28,539	31,140	29,337	29,731	27,571	27,046	27,330	23,991	19,806	19,466	0	0	0
Gross profit
-36	271	570	915	1,719	2,227	7,867	11,104	17,114	23,275	26,604	30,276	28,670	28,635	26,247	25,682	29,711	28,009	25,703	29,851	0	0	0
Advertising expenses
-	-	-	-	-	-	-	3,803	6,065	8,355	8,182	8,594	8,591	7,233	7,464	7,562	8,208	11,353	13,192	14,154	0	0	0
Selling expenses
565	841	1,119	1,169	1,293	1,838	3,858	4,835	7,704	9,030	9,257	9,892	8,242	8,665	8,749	9,012	13,955	13,302	13,024	13,734	0	0	0
General and administrative expenses
3,554	3,483	2,507	2,431	3,724	3,919	4,563	4,648	5,690	6,659	7,165	7,718	6,358	6,574	6,342	6,092	5,230	6,003	5,928	5,951	0	0	0
Impairment loss on intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-
Provision for doubtful debt
-8,139	-6,648	-318	-265	7,820	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Compensation paid to customers - note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-
Administrative penalty - note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-
Research and development expenses
-	-	-	-	-	-	-	4,020	3,735	3,426	3,089	2,766	2,890	3,011	3,127	3,228	4,517	4,496	4,480	4,475	0	0	0
Impairment loss on loan receivables
-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
Impairment loss on intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-
Total operating expenses
-2,822	-1,125	4,505	4,479	31,304	31,551	31,403	34,861	21,967	26,243	28,044	31,589	28,969	28,371	27,233	25,174	35,969	40,809	49,946	51,637	0	0	0
Loss from operations
2,785	1,396	-3,935	-3,564	-29,584	-29,323	-23,536	-23,757	-4,852	-2,968	-1,439	-1,312	-298	264	-986	508	-6,257	-12,799	-24,242	-21,786	0	0	0
Interest income
2	2	2	1	311	0	0	-	0	-	-	1,330	1,170	1,208	1,205	1,344	1,183	891	655	296	0	0	0
Interest expense
201	259	213	206	364	259	260	283	217	217	216	154	74	172	271	367	344	247	165	84	0	0	0
Fair value adjustment on warrants
469	459	215	227	145	287	362	324	460	264	567	577	341	393	0	-	0	0	-	-	-	-	-
Other expense
-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
0	0	-	-	0	0	-	-	638	637	316	1,093	0	0	0	-	-	-	0	0	0	0	0
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-
Total other income, net
802	752	554	518	-749	-691	-296	-35	1,570	1,417	1,729	2,847	3,703	3,650	3,159	2,147	838	642	488	212	0	0	0
Loss before income taxes
3,587	2,148	-3,380	-3,045	-30,334	-30,015	-23,832	-23,792	-3,282	-1,550	289	1,534	3,404	3,914	2,173	2,656	-5,419	-12,157	-23,753	-21,573	0	0	0
Income tax expenses
2,653	2,653	2,711	2,653	1,957	1,967	1,740	1,319	-4,031	-3,794	-4,091	-3,313	621	983	1,618	1,846	1,105	694	-2,150	-1,576	0	0	0
Net loss
934	-504	-6,092	-5,698	-32,291	-31,982	-25,572	-25,112	749	2,243	4,381	4,848	2,782	2,931	554	809	-6,524	-12,852	-21,603	-19,997	0	0	0
Foreign currency translation adjustment
120	-840	-2,746	-2,753	-1,630	-4,596	-3,029	-2,957	-2,311	887	706	-208	0	0	0	-	3,082	1,628	729	546	0	0	0
Comprehensive loss
1,055	-1,344	-8,838	-8,452	-33,922	-36,579	-28,602	-28,070	-1,562	3,131	5,088	4,639	1,761	3,187	1,654	2,880	-3,442	-11,223	-20,874	-19,450	0	0	0
Net loss per share
Basic (in Dollars per share)
-0.05	-0.50	-0.38	1.61	-0.71	-3.12	-0.28	-10.54	-0.57	-0.22	-0.07	2.15	0.02	0.11	0.02	0.04	0.03	-0.06	0.06	-	-	-	-
Diluted (in Dollars per share)
-0.05	-0.50	-0.38	1.61	-0.71	-3.12	-0.28	-10.54	-0.57	-0.22	-0.07	2.15	0.02	0.11	0.02	0.04	0.03	-0.06	0.06	-	-	-	-
Weighted average number of common shares outstanding
Basic (in Shares)
2,637	2,637	2,637	2,556	2,210	2,210	2,210	2,210	2,210	2,210	2,210	-34,353	15,288	14,326	13,024	12,464	12,024	11,560	9,993	-	-	-	-
Diluted (in Shares)
2,637	2,637	2,637	2,556	2,210	2,210	2,210	2,210	2,210	2,210	2,210	-34,359	15,288	14,326	13,030	12,464	12,024	11,560	9,993	-	-	-	-
Net income (loss) per share Basic and diluted (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.68	-0.63	-1.01	0.23
Weighted average number of common shares outstanding Basic and diluted (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,993	9,490	9,400	9,398